Oxford BioMedica’s full year results highlight that the manufacturing capacity expansion has progressed with all the work expected to be completed in the next six months. A portfolio review in Q1 2016 has led the group to focus on three internal product candidates (all currently pre-clinical) with trials anticipated to commence or data generated from each in 2016. 2015 has been a year the group has undertaken a substantial capex programme in order to increase its manufacturing space in order to ....
